A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01163929 |
|
Recruitment Status
:
Withdrawn
(Study closed by Protocol Review Monitoring Committee because of lack of accrual)
First Posted
: July 16, 2010
Last Update Posted
: October 24, 2012
|
Sponsor:
University of Kansas
Collaborator:
Novartis
Information provided by (Responsible Party):
University of Kansas Medical Center ( University of Kansas )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Recruitment Status : | Withdrawn |
|---|---|
| Actual Primary Completion Date : | March 2012 |
| Actual Study Completion Date : | March 2012 |